Technical Analysis for DARE - Dare Bioscience, Inc.

Grade Last Price % Change Price Change
F 3.18 0.00% 0.00
DARE closed unchanged on Wednesday, November 20, 2024, on 48 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
1 Watcher
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Down Down Down

Date Alert Name Type % Chg
Boomer Sell Setup Bearish Swing Setup 0.00%
Calm After Storm Range Contraction 0.00%
NR7 Range Contraction 0.00%
NR7-2 Range Contraction 0.00%
Narrow Range Bar Range Contraction 0.00%
Doji - Bullish? Reversal 0.00%
Wide Bands Range Expansion 0.00%
Oversold Stochastic Weakness 0.00%
Boomer Sell Setup Bearish Swing Setup 0.00%
Calm After Storm Range Contraction 0.00%

   Recent Intraday Alerts

Alert Time
Possible NR7 about 18 hours ago
1.5x Volume Pace about 22 hours ago
Possible NR7 2 days ago
60 Minute Opening Range Breakout 2 days ago
Lower Bollinger Band Support 2 days ago

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Dare Bioscience, Inc. Description

Dare Bioscience, Inc., formerly Cerulean Pharma Inc., is a healthcare company. The Company is focused on the development and commercialization of products in women’s reproductive health. Its lead product candidate is Ovaprene, a clinical stage, non-hormonal contraceptive ring. The Company is developing Ovaprene to provide protection over multiple weeks of use and require no intervention at the time of intercourse. Ovaprene has a custom intravaginal ring design, with a permeable mesh in the center of the ring that creates a partial barrier to sperm, and a mechanism to release locally acting spermiostatic agents through the ring. The combination of these two complementary approaches produces attractive contraceptive efficacy outcomes that are consistent with the effective barrier option, the diaphragm, and short-acting hormonal options, such as oral pill, patches and vaginal ring.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Drugs Birth Control Vagina Women's Health Diaphragm

Is DARE a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 7.56
52 Week Low 3.05
Average Volume 43,112
200-Day Moving Average 4.29
50-Day Moving Average 3.55
20-Day Moving Average 3.83
10-Day Moving Average 3.72
Average True Range 0.25
RSI (14) 35.90
ADX 36.09
+DI 17.61
-DI 29.84
Chandelier Exit (Long, 3 ATRs) 3.86
Chandelier Exit (Short, 3 ATRs) 3.92
Upper Bollinger Bands 4.62
Lower Bollinger Band 3.04
Percent B (%b) 0.09
BandWidth 41.33
MACD Line -0.08
MACD Signal Line 0.05
MACD Histogram -0.1312
Fundamentals Value
Market Cap 313.43 Million
Num Shares 98.6 Million
EPS -0.48
Price-to-Earnings (P/E) Ratio -6.63
Price-to-Sales 36.27
Price-to-Book 3.44
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 3.21
Resistance 3 (R3) 3.21 3.21 3.21
Resistance 2 (R2) 3.21 3.20 3.21 3.20
Resistance 1 (R1) 3.19 3.19 3.19 3.19 3.20
Pivot Point 3.19 3.19 3.19 3.19 3.19
Support 1 (S1) 3.17 3.18 3.17 3.17 3.16
Support 2 (S2) 3.17 3.17 3.17 3.16
Support 3 (S3) 3.15 3.17 3.16
Support 4 (S4) 3.15